{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:21:28Z","timestamp":1791814888878,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaip.2025.11.039","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:39:13Z","timestamp":1770284353000},"page":"375-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Updates on the Current and Evolving Treatment for Hereditary Angioedema"],"prefix":"10.1016","volume":"14","author":[{"given":"Paula J.","family":"Busse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Shen","family":"Fok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohini Shah","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary J.","family":"Longhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.11.039_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib2","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.039_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 Guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.039_bib4","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jaci.2021.05.016","article-title":"Consensus on treatment goals in hereditary angioedema: a global Delphi initiative","volume":"148","author":"Maurer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-9-44","article-title":"The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency","volume":"9","author":"Zotter","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2025.11.039_bib6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2024.12.680","article-title":"Short-term prophylaxis and on-demand treatment in HAE-C1INH in the last ten years","volume":"155","author":"Colque-Bayona","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/ab8fe636-8b5b-420e-9cbf-1bef0a19b63f","article-title":"Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment","volume":"8","author":"Maurer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2025.11.039_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2500\/aap.2011.32.3440","article-title":"Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials","volume":"32","author":"Banta","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.11.039_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.anai.2013.06.021","article-title":"Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks","volume":"111","author":"Craig","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-025-00969-0","article-title":"Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedema","volume":"21","author":"Betschel","year":"2025","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","article-title":"Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks","volume":"124","author":"Craig","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","article-title":"Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial","volume":"107","author":"Lumry","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaci.2010.07.021","article-title":"Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema","volume":"126","author":"Zuraw","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.anai.2013.12.004","article-title":"Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial","volume":"112","author":"Riedl","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa0905079","article-title":"Ecallantide for the treatment of acute attacks in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","article-title":"EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema","volume":"104","author":"Levy","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2314192","article-title":"Oral sebetralstat for on-demand treatment of hereditary angioedema attacks","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib20","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJM199606203342503","article-title":"Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate","volume":"334","author":"Waytes","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1537-2995.1998.38698326333.x","article-title":"A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema","volume":"38","author":"Kunschak","year":"1998","journal-title":"Transfusion"},{"key":"10.1016\/j.jaip.2025.11.039_bib22","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jaip.2020.02.043","article-title":"Clinical characteristics and safety of plasma-derived C1-inhibitor therapy in children and adolescents with hereditary angioedema\u2014a long-term survey","volume":"8","author":"Farkas","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.039_bib23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jaip.2016.04.018","article-title":"Safety and usage of C1-inhibitor in hereditary angioedema: Berinert registry data","volume":"4","author":"Riedl","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.039_bib24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2005.05.019","article-title":"A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema","volume":"116","author":"van Doorn","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaci.2007.04.028","article-title":"Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor","volume":"120","author":"Schneider","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2024.12.1079","article-title":"Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines","volume":"155","author":"Cohn","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2249.2012.04574.x","article-title":"Safety and efficacy of icatibant self-administration for acute hereditary angioedema","volume":"168","author":"Boccon-Gibod","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cpdd.138","article-title":"Pharmacokinetics of single and repeat doses of icatibant","volume":"4","author":"Leach","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jaip.2025.11.039_bib29","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jaip.2020.02.038","article-title":"Validation of the Angioedema Control Test (AECT)\u2014a patient-reported outcome instrument for assessing angioedema control","volume":"8","author":"Weller","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.039_bib30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.anai.2024.07.018","article-title":"Development and validation of a US quality of life instrument for hereditary angioedema due to C1 inhibitor deficiency","volume":"133","author":"Castaldo","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9157895","article-title":"Angioedema Activity Score (AAS): a valid and reliable tool to use in Asian patients","volume":"2019","author":"Kulthanan","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaip.2025.11.039_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib33","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib34","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2025.11.039_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaip.2023.09.009","article-title":"Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: results from the phase 3 SPRING Study","volume":"12","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.039_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.11.039_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib39","first-page":"AB194","article-title":"Long-term safety and efficacy of oral deucrictibant for prophylaxis in hereditary angioedema: results of the CHAPTER-1 open-label extension study","volume":"155","author":"Riedl","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13223-019-0328-3","article-title":"Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks","volume":"15","author":"Bernstein","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1576235","article-title":"Real-world evidence of the effectiveness and utilization of subcutaneous C1INH long-term prophylaxis in patients with HAE in Spain and Germany","volume":"16","author":"Maurer","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.anai.2014.05.028","article-title":"A phase 1 study investigating DX-2930 in healthy subjects","volume":"113","author":"Chyung","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib43","doi-asserted-by":"crossref","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","article-title":"Inhibition of plasma kallikrein by a highly specific active site blocking antibody","volume":"289","author":"Kenniston","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaip.2025.11.039_bib44","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/all.15011","article-title":"Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE Study","volume":"77","author":"Banerji","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.039_bib45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.anai.2025.06.004","article-title":"Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final results","volume":"135","author":"Farkas","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib46","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.jaci.2018.06.014","article-title":"Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation","volume":"142","author":"Cao","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/all.16351","article-title":"Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: phase 3 open-label extension study","volume":"80","author":"Reshef","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.039_bib48","doi-asserted-by":"crossref","first-page":"AB197","DOI":"10.1016\/j.jaci.2024.12.614","article-title":"Long-term efficacy of garadacimab for hereditary angioedema in patients with or without prior exposure in a phase 3 open-label extension study","volume":"155","author":"Anderson","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.12.419","article-title":"Efficacy and safety of bradykinin B2 receptor inhibition with oral PHVS416 in treating hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial","volume":"151","author":"Maurer","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.039_bib50","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.123.001740","article-title":"STAR-0215 is a novel, long-acting monoclonal antibody inhibitor of plasma kallikrein for the potential treatment of hereditary angioedema","volume":"387","author":"Bedian","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaip.2025.11.039_bib51","series-title":"Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): initial combined results from ALPHA-STAR and ALPHA-SOLAR","author":"Lumry","year":"2024"},{"key":"10.1016\/j.jaip.2025.11.039_bib52","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib53","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1056\/NEJMoa2405734","article-title":"CRISPR-based therapy for hereditary angioedema","volume":"392","author":"Cohn","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.039_bib54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaip.2023.12.025","article-title":"Clinical progress in hepatic targeting for novel prophylactic therapies in hereditary angioedema","volume":"12","author":"Riedl","year":"2024","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:37:10Z","timestamp":1780126630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825011456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2213219825011456"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.11.039","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on the Current and Evolving Treatment for Hereditary Angioedema","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}